Biotech Laboratories (Pty) Ltd v Beecham Group PLC and Another

Smith-Kline Beecham (second respondent) marketed Augmentin, a medicine consisting of amoxycillin and potassium clavulanate, registered under the Medicines and Related Substances Control Act 101 of 1965. Dr Kritzinger, Smith-Kline Beecham's medical director, prepared a package insert for the medicine, which was required for registration purposes. The insert was compiled using skill and judgment, drawing from various data sheets prepared by Beecham Group PLC (first respondent, the parent company), with original language and synopses prepared by Dr Kritzinger and his staff. The insert underwent a lengthy approval process with the Medicines Control Council (MCC) during 1980-1982, with various amendments and discussions, until final approval was obtained. After the patents on Augmentin lapsed, Biotech Laboratories (appellant) applied to register the same chemical composition under the name Bio-Amoksoklav. At the MCC's behest, Biotech copied Smith-Kline Beecham's package insert substantially and obtained registration. Biotech sold its product with this copied package insert. Smith-Kline Beecham obtained an interdict in the court below (per Swart J) restraining Biotech from infringing its copyright. Biotech appealed.

• Whether the package insert was an 'original' literary work eligible for copyright protection under section 2(1) of the Copyright Act 98 of 1978
• Whether copyright in the package insert vested in the State by virtue of section 5(2) of the Copyright Act 98 of 1978, on the basis that it was made 'by or under the direction or control of the state'
• Whether the MCC's approval process constituted 'direction or control' for purposes of section 5(2)
• Whether substantial copying of the package insert constituted copyright infringement

The appeal was dismissed with costs, including costs consequent upon the employment of two counsel. The interdict granted by Swart J in the court below restraining Biotech from infringing Smith-Kline Beecham's copyright in the package insert was upheld.

The binding legal principles established by this judgment are: (1) Originality under section 2(1) of the Copyright Act 98 of 1978 must be assessed in relation to the work as a whole, not by dissecting it into parts and examining each part separately. Where sufficient skill and judgment have been exercised in devising the arrangement of the whole work, this can be decisive in determining copyright protection. (2) Under section 5(2) of the Copyright Act 98 of 1978, for a work to be made 'by or under the direction or control of the state', the production of the work must be the principal object of State direction and control, not merely an incidental or peripheral consequence of some generalized governmental licensing or monitoring power. (3) The direction and control contemplated by section 5(2) must be directly and specifically expressed with respect to the work in question, and should not be inferred from the fact of some residual or ultimate government veto or approval power. (4) Regulatory approval processes that involve reviewing, commenting on, or requiring amendments to a work do not constitute 'direction or control' for purposes of section 5(2) where the State does not control the intellectual effort involved in the genesis of the work. (5) Copyright once conferred on a work and vested in a party remains so vested unless transmitted under section 22 of the Act. Where copyright vests in an employer under section 21(1)(d) when an employee creates a work, subsequent regulatory approval does not divest that copyright or transfer it to the State.

The court made several notable obiter observations: (1) Harms JA traced the historical development of copyright law from Roman times through the UK Statute of Anne (1709) to modern South African law, noting that the initial purpose of copyright was more about commercial monopoly and control of printing than protecting authors' rights. (2) The court noted that while the Copyright Act 98 of 1978 initially attempted to adopt a Continental approach emphasizing authors' moral rights, amendments (particularly to section 21) quickly reverted to the Anglo-American model emphasizing commercial rights of employers and entrepreneurs. The court expressed skepticism about the philosophical premise that copyright law is primarily designed to reward and incentivize creators. (3) The court observed that allowing the State to 'reap what it did not sow' would not be in the spirit of constitutional values, suggesting that section 5(2) should be interpreted restrictively. (4) The court commented on the MCC's policy concerns, noting that while identical package inserts for the same medicines may be a 'commendable ideal', this does not entitle the MCC to disregard parties' statutory proprietary rights. The evidence showed that identical inserts were not necessary and at least one competitor had produced an acceptable non-infringing insert. (5) The court noted (without deciding) that it may be open to debate whether a commissioned work falls under 'direction' or 'control' for purposes of section 5(2). (6) The court observed it was unnecessary to consider whether copyright protection might be affected where information can be presented in only one format (such as mathematical formulas, cricket batting lists, or alphabetical lists), as this was not such a case.

This case is significant in South African copyright law for several reasons: (1) It clarifies the test for originality in compilations and literary works, establishing that originality must be assessed in relation to the work as a whole, not its individual parts; (2) It provides authoritative interpretation of section 5(2) of the Copyright Act 98 of 1978 regarding State copyright, establishing a restrictive approach requiring the State to have principal, direct and specific control over the creation of a work, not merely regulatory approval power; (3) It confirms that regulatory approval processes (such as those conducted by the MCC under the Medicines Act) do not automatically vest copyright in the State, protecting the intellectual property rights of pharmaceutical companies and other regulated entities; (4) It demonstrates that copyright law principles apply even in the context of generic medicines and public health regulation, and that regulatory bodies cannot disregard proprietary rights based on policy considerations; (5) The case is important in the pharmaceutical industry context, establishing that package inserts prepared by innovator companies are protected by copyright and cannot simply be copied by generic manufacturers, even where the underlying patent has expired.